Eli Lilly has unveiled a $27bn investment in US manufacturing facilities as the pharmaceutical industry prepares for the threat of tariffs and mounts a charm offensive aimed at President Donald Trump’s new administration.
The Indianapolis-based drugmaker announced plans to plough money into four new US production plants, more than doubling its investments announced since 2020 to $50bn.
The investment, announced by Eli Lilly at an event held near the White House on Wednesday, marks the latest effort by the pharmaceutical company to ingratiate itself with the Trump administration.
您已阅读20%（583字），剩余80%（2290字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。